Market Size (Value & Volume) & Forecasts and Trend Analyses, by Products
Market Size (Value & Volume) & Forecasts and Trend Analyses, by Therapeutic Area
Market Size (Value & Volume) & Forecasts and Trend Analyses, by based on End-User
Market Size (Value & Volume) & Forecasts and Trend Analyses, by based on region
Europe Connected Smart Drug Delivery Systems Market Revenue by Country,
North America Connected Smart Drug Delivery Systems Market Revenue by Country,
Asia Pacific Connected Smart Drug Delivery Systems Market Revenue by Country,
Latin America Connected Smart Drug Delivery Systems Market Revenue by Country,
Middle East & Africa Connected Smart Drug Delivery Systems Market Revenue by Country,
Competitive Landscape
Latest Strategic Developments
Companies Mentioned
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Connected Smart Drug Delivery Systems Market Snapshot
Chapter 4. Global Connected Smart Drug Delivery Systems Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Industry Analysis – Porter’s Five Forces Analysis
4.6. Competitive Landscape & Market Share Analysis
4.7. COVID 19 Impact Analysis
Chapter 5. Market Segmentation 1: By Products Estimates & Trend Analysis
5.1. By Products & Market Share, 2024 & 2034
5.2. Market Size (Value & Volume) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Products:
5.2.1. Connected Inhalers
5.2.2. Connected Autoinjectors
5.2.3. Connected Needle-Free Injectors
5.2.4. Connected Pen injectors
5.2.5. Connected Insulin Pumps
5.2.6. Connected Wearable Injectors/Patch Pumps
5.2.7. Add-On Sensors
Chapter 6. Connected Smart Drug Delivery Systems Market Segmentation 2: By Applications Estimates & Trend Analysis
6.1. By Therapeutic Area Analysis & Market Share, 2024 & 2034
6.2. Market Size (Value & Volume) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Therapeutic Area:
6.2.1. Metabolic Disorders
6.2.2. Neurological Disorders
6.2.3. Respiratory Disorders
6.2.4. Others
Chapter 7. Connected Smart Drug Delivery Systems Market Segmentation 3: By End-Users Estimates & Trend Analysis
7.1. By Therapeutic Area Analysis & Market Share, 2024 & 2034
7.2. Market Size (Value & Volume) & Forecasts and Trend Analyses, 2021 to 2034 for the following By End-Users:
7.2.1. Hospital
7.2.2. Clinics
7.2.3. Homecare
Chapter 8. Connected Smart Drug Delivery Systems Market Segmentation 4: Regional Estimates & Trend Analysis
8.1. North America
8.1.1. North America Connected Smart Drug Delivery Systems Market Revenue (US$ Million) and Volume (No. of Units) Estimates and Forecasts by Products, 2021-2034
8.1.2. North America Connected Smart Drug Delivery Systems Market Revenue (US$ Million) and Volume (No. of Units) Estimates and Forecasts by Therapeutic Area, 2021-2034
8.1.3. North America Connected Smart Drug Delivery Systems Market Revenue (US$ Million) and Volume (No. of Units) Estimates and Forecasts by End-Users, 2021-2034
8.1.4. North America Connected Smart Drug Delivery Systems Market Revenue (US$ Million) and Volume (No. of Units) Estimates and Forecasts by Country, 2021-2034
8.1.4.1. U.S.
8.1.4.2. Canada
8.2. Europe
8.2.1. Europe Connected Smart Drug Delivery Systems Market Revenue (US$ Million) and Volume (No. of Units) By Products, 2021-2034
8.2.2. Europe Connected Smart Drug Delivery Systems Market Revenue (US$ Million) and Volume (No. of Units) By Therapeutic Area, 2021-2034
8.2.3. Europe Connected Smart Drug Delivery Systems Market Revenue (US$ Million) and Volume (No. of Units) By End-Users, 2021-2034
8.2.4. Europe Connected Smart Drug Delivery Systems Market Revenue (US$ Million) and Volume (No. of Units) by Country, 2021-2034
8.2.4.1. Germany
8.2.4.2. Poland
8.2.4.3. France
8.2.4.4. Italy
8.2.4.5. Spain
8.2.4.6. UK
8.2.4.7. Rest of Europe
8.3. Asia Pacific
8.3.1. Asia Pacific Connected Smart Drug Delivery Systems Market Revenue (US$ Million) and Volume (No. of Units) By Products, 2021-2034
8.3.2. Asia Pacific Connected Smart Drug Delivery Systems Market Revenue (US$ Million) and Volume (No. of Units) By Therapeutic Area, 2021-2034
8.3.3. Asia Pacific Connected Smart Drug Delivery Systems Market Revenue (US$ Million) and Volume (No. of Units) By End-Users, 2021-2034
8.3.4. Asia Pacific Connected Smart Drug Delivery Systems Market Revenue (US$ Million) and Volume (No. of Units) by Country, 2021-2034
8.3.4.1. China
8.3.4.2. India
8.3.4.3. Japan
8.3.4.4. Australia
8.3.4.5. Rest of Asia Pacific
8.4. Latin America
8.4.1. Latin America Connected Smart Drug Delivery Systems Market Revenue (US$ Million) and Volume (No. of Units) By Products, (US$ Million) 2021-2034
8.4.2. Latin America Connected Smart Drug Delivery Systems Market Revenue (US$ Million) and Volume (No. of Units) By Therapeutic Area, (US$ Million) 2021-2034
8.4.3. Latin America Connected Smart Drug Delivery Systems Market Revenue (US$ Million) and Volume (No. of Units) By End-Users, (US$ Million) 2021-2034
8.4.4. Latin America Connected Smart Drug Delivery Systems Market Revenue (US$ Million) and Volume (No. of Units) by Country, (US$ Million) 2021-2034
8.4.4.1. Brazil
8.4.4.2. Rest of Latin America
8.5. MEA
8.5.1. MEA Connected Smart Drug Delivery Systems Market Revenue (US$ Million) and Volume (No. of Units) By Products, (US$ Million) 2021-2034
8.5.2. MEA Connected Smart Drug Delivery Systems Market Revenue (US$ Million) and Volume (No. of Units) By Therapeutic Area, (US$ Million) 2021-2034
8.5.3. MEA Connected Smart Drug Delivery Systems Market revenue (US$ Million) and volume (No. of Units) By End-Users, (US$ Million) 2021-2034
8.5.4. MEA Connected Smart Drug Delivery Systems Market revenue (US$ Million) and volume (No. of Units) by Country, (US$ Million) 2021-2034
8.5.4.1. South Africa
8.5.4.2. GCC Countries
8.5.4.3. Rest of MEA
Chapter 9. Competitive Landscape
9.1. Major Mergers and Acquisitions/Strategic Alliances
9.2. Company Profiles
9.2.1. BIOCORP
9.2.2. Elcam Drug Delivery Devices (E3D)
9.2.3. Novo Nordisk
9.2.4. Merck
9.2.5. Pneuma Respiratory
9.2.6. H&T Presspart
9.2.7. Nemera
9.2.8. Ypsomed Holdings
9.2.9. Unolife Corporation
9.2.10. Quio Technologies
9.2.11. SHL Group
9.2.12. Haselmeier Inc.
9.2.13. Portal Instruments Inc
9.2.14. West Pharmaceutical Services Inc.
9.2.15. Emperra GmbH E-Health Technologies
9.2.16. Amiko Digital Health Limited
9.2.17. Cognita Labs
9.2.18. DIAMESCO CO., Ltd.?
9.2.19. Eitan Medical (Q Core Medical Ltd., Avoset Health, Sorrel Medical)
9.2.20. Enable Injections
9.2.21. Bigfoot Biomedical Inc.
9.2.22. Medtronic Plc
9.2.23. Companion Medical
9.2.25. Cohero Health, Inc.
9.2.26. Propeller Health
9.2.27. Pendiq Intelligent Diabetes Care
9.2.28. Phillips-Medisize
9.2.29. Becton, Dickinson and Company (BD)
9.2.30. Noble International Inc
9.2.31. etectRx
9.2.32. Aterica Inc.
9.2.33. Findair Sp. z o. o.
9.2.34. Recipharm AB
9.2.35. Aero Pump GmbH
9.2.36. Jiangsu Delfu medical device Co.,Ltd
8.3. List of Other Prominent Players
This study employed a multi-step, mixed-method research approach that integrates:
This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.
Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.
Secondary data for the market study was gathered from multiple credible sources, including:
These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.
Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.
Primary interviews for this study involved:
Interviews were conducted via:
Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.
All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.
The data validation process included:
This ensured that the dataset used for modelling was clean, robust, and reliable.
The bottom-up approach involved aggregating segment-level data, such as:
This method was primarily used when detailed micro-level market data were available.
The top-down approach used macro-level indicators:
This approach was used for segments where granular data were limited or inconsistent.
To ensure accuracy, a triangulated hybrid model was used. This included:
This multi-angle validation yielded the final market size.
Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.
Given inherent uncertainties, three scenarios were constructed:
Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.